Elbit Imaging Announces That Gamida Cell's Initiation Of A Phase I Study Of Nam-Nk Cells Immunotherapy Program For Non-Hodgkin Lymphoma And Multiple Myeloma
TEL AVIV, ISRAEL / ACCESSWIRE / January 17, 2018 / Elbit Imaging Ltd. ("EI" or the "Company") (TASE: EMITF, NASDAQ: EMITF) announced today, further to its press release dated December 12, 2017, that Gamida Cell Ltd. ("Gamida"), an indirect shareholding of the Company, has announced its initiation of a Phase I study evaluating its proprietary NAM-expanded natural killer cells (NAM-NK Cells) in patients with relapsed or refractory CD20+...
Read more








